



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- November 06, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

NSE Symbol: FDC

Sub: Press Release on Q2 - FY 2025-26 Results.

Dear Sir/Ma'am,

Please find attached herewith a Press Release issued in relation to the Unaudited Consolidated Financial Results of the Company for the Quarter and half year ended September 30, 2025.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Legal Head

M No.: FCS-8948

FDC Limited announces Q2 FY26 results

Mumbai, November 5, 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) has announced its financial results for the second quarter and half year ended September 30, 2025.

Consolidated Financial Results for Q2 FY26 and H1 FY26:

(Rs. in crores)

Particulars	Q2 FY26	Q2 FY25	Y-o-Y Grw %	H1 FY26	H1 FY25	Y-o-Y Grw%
Revenue from operations	473	514	-7.9%	1,121	1,152	-2.7%
EBITDA*	35	70	-49.7%	176	217	-19.0%
EBITDA Margin*	7.5%	13.7%		15.7%	18.8%	
PBT	38	90	-57.6%	198	253	-21.7%
PAT	28	72	-60.6%	150	191	-21.6%
EPS (Rs.)	1.74	4.43	-60.7%	9.20	11.74	-21.6%

*Excluding fair value loss on financial instruments in Q2 FY26

Commenting on the results:

We had a subdued performance in Q2 FY26, with revenue from operations of Rs. 473 crores, registering a de-growth of 7.9% Y-o-Y, majorly because of lower sales in Domestic Formulations business. Export Formulations business was up by 3.5% Y-o-Y and API business reflected growth of 6.8% Y-o-Y. For H1 FY26, revenue from operations stood at Rs. 1,121 crores with a de-growth of 2.7%.

The US business continues to show good signs of recovery as the past challenges are now addressed and business has shown good momentum with revenue of Rs. 23 crores from supplies made during H1 FY26, reflecting a 29.9% Y-o-Y growth. However, overall revenue of US business is down by 31.2% Y-o-Y primarily due to lower profit share (impacted due to recall) from the US partners.

Our EBITDA stood at Rs. 35 crores, with margins at 7.5% compared to 13.7% last year. EBITDA is down majorly due to certain strategic expenditure incurred for future business growth particularly higher Research and Development expenses and higher employee costs for moderate expansion of field force.

CORPORATE OFFICE : C - 11 & 12, Dalia Industrial Estate, Oshiwara Village, Off. Link Road, Near Fun Republic, Andheri (W), Mumbai - 400 053.
Tel.: +91-22-6910 7100
E-mail: fdc@fdcindia.com Website: www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 Fax: 0240-255 4299
E-mail: waluj@fdcindia.com CIN: L24239MH1940PLC003176

Business Segment-wise Sales Performance

(Rs. in crores)

Particulars	Q2 FY26	Y-o-Y Grw %	H1 FY26	Y-o-Y Grw%
Revenue from operations	473	-7.9%	1,121	-2.7%
Domestic Formulations	378	-10.7%	960	-1.5%
Export Formulations (US)	16	-38.4%	31	-31.2%
Export Formulations (Non-US)	46	34.3%	70	-6.6%
APIs	31	6.8%	57	5.0%

Domestic Formulations:

Domestic Formulations sales stood at Rs. 378 crores for Q2 FY26, reflecting a decline of 10.7% Y-o-Y. For the first half of FY26, Domestic Formulations sales were Rs. 960 crores, registering a de-growth of 1.5% compared to the corresponding period last year. Domestic Formulations business contributed 80% to total consolidated sales during the quarter and 86% for H1 FY26.

According to the secondary sales data by IQVIA (MAT September 30, 2025), the Company recorded a 6.7% growth. Electral continued to strengthen its market position, rising to 15th rank in the IPM (MAT September 30, 2025) from 18th in the same period last year.

Export Formulations:

Export Formulations sales stood at Rs. 62 crores in Q2 FY26, registering a growth of 3.5% Y-o-Y and 54.2% Q-o-Q, contributing 13% to company's consolidated sales. For the first half of FY26, Export Formulations sales were Rs. 101 crores, reflecting a 15.9% decline compared to the same period last year. The lower performance during H1 was primarily due to lower supplies in Q1 FY26; however, a revival in supplies during Q2 FY26 has supported improved momentum in the business.

During the quarter, the Company received U.S. FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.2% and Moxifloxacin Hydrochloride Ophthalmic Solution USP 0.5%. These approvals further strengthen FDC's ophthalmic portfolio and reinforce its commitment to expanding its presence in the regulated markets.

APIs:

API business registered sales of Rs. 31 crores in Q2 FY26, up by 6.8% Y-o-Y and 21.2% Q-o-Q and accounted for 7% of total consolidated sales. During H1 FY26, the API business grew by 5.0% registering sales of Rs. 57 crores.

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Formulations. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.